Epigenetics of Multiple Sclerosis: towards a better understanding of pathogenic mechanisms and tailored disease management

Multiple Sclerosis (MS) is a chronic inflammatory disease of the central nervous system and a leading cause of incurable progressive disability in young adults.

We propose that epigenetic mechanisms, which integrate cues from both genetic variants and environmental exposures, mediate MS development and that more precise therapies  can be developed based on understanding and correcting aberrant epigenetic states.

We will exploit the stable and reversible nature of epigenetic marks to: (i) Identify novel modifiable mechanisms that trigger MS and predispose for disease progression, (ii) Develop precise therapeutic strategies based on reversing causal epigenetic states, and (iii) Characterize epigenetic marks that can serve as sensitive and specific biomarkers.

To identify aberrant epigenetic changes, we utilize unique clinical cohorts combined with the cutting-edge molecular and analytical methodologies to capture relevant cells and measure their (epi)genomic states.

Such states are functionally validated and the therapeutic potential of their specific targeting using multiple tools is investigated in comprehensive in-vitro and in-vivo models.

Our findings have the potential to advance the understanding of molecular mechanisms underlying MS facilitating the development of more specific therapies and tailored treatment decisions, in turn setting the stage for precision medicine in the management of MS.